Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 225

Results For "MIT"

4656 News Found

Ajanta Pharma's Q1 FY24 consolidated PAT up at Rs. 208.12 Cr
News | July 28, 2023

Ajanta Pharma's Q1 FY24 consolidated PAT up at Rs. 208.12 Cr

The company has reported total income of Rs. 1052.79 crores during the period ended June 30, 2023


Biocon Foundation releases 2nd edition of consensus guidelines for head & neck cancer
News | July 28, 2023

Biocon Foundation releases 2nd edition of consensus guidelines for head & neck cancer

Marks the World Head & Neck Cancer Day at the OCTF Conference


Cipla reports jump in Q1FY24 consolidated PAT to Rs. 995.70 Cr
News | July 27, 2023

Cipla reports jump in Q1FY24 consolidated PAT to Rs. 995.70 Cr

Cipla has reported total income of Rs. 6465.18 crores during the period ended June 30, 2023


Eugia Pharma receives USFDA approval for Plerixafor Injection
Drug Approval | July 26, 2023

Eugia Pharma receives USFDA approval for Plerixafor Injection

The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023


Teva Pharmaceuticals engages Honeywell to help reduce carbon impact
Sustainability | July 26, 2023

Teva Pharmaceuticals engages Honeywell to help reduce carbon impact

Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model


Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr
News | July 26, 2023

Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr

Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24


Lupin receives approval from TGA Australia for Tiotropium Dry Powder
Drug Approval | July 26, 2023

Lupin receives approval from TGA Australia for Tiotropium Dry Powder

Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule


NATCO files generic Erdafitinib Tablets in USA
Drug Approval | July 26, 2023

NATCO files generic Erdafitinib Tablets in USA

Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma